Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.

Marina Elena CazzanigaI ValliniE MontagnaD AmorosoR BerardiA ButeraK CagossiL CavannaM CiccareseS CinieriE CretellaE De ConciliisA FebbraroF FerraùA FerziA BaldelliA FontanaA R GambaroO GarroneV GebbiaD GeneraliL GianniF GiovanardiA GrassadoniaV LeonardiP MarchettiS SartiA MusolinoM NicoliniC PutzuF RiccardiD SantiniS SaracchiniM G SarobbaM G SchintuG ScognamiglioP SpadaroC TavernitiD TonioloP TralongoA TurlettiR ValenzaM R ValerioP ViciP Di MauroV CogliatiS CapiciL ClivioV Torrinull null

Published in: Breast cancer research and treatment (2021)

This analysis represents the largest series of TNBC patients treated with mCHT in a real-life setting and provides further insights into the advantages of using this strategy even in this poor prognosis subpopulation.

Keyphrases

poor prognosis
end stage renal disease
long non coding rna
ejection fraction
chronic kidney disease
newly diagnosed
small cell lung cancer
squamous cell carcinoma
peritoneal dialysis
patient reported outcomes
rectal cancer
chemotherapy induced